- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
InflaRx N.V. (IFRX)
Track the InflaRx share price today and view real-time IFRX share price data, including charts, technicals, and key financials. View the IFRX premarket stock price ahead of the market session or assess the after hours quote. Explore IFRX stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the InflaRx Stock Price Today?
The InflaRx stock price today is 1.700.
What Is the Stock Symbol for InflaRx?
The stock symbol for InflaRx is ""IFRX.""
What Stock Exchange Does InflaRx Trade On?
InflaRx is listed and trades on the NASDAQ stock exchange.
Is InflaRx a Good Stock to Buy?
Determining whether InflaRx or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IFRX quote. (ISIN: NL0012661870)
What Is the InflaRx Stock Price Today?
The InflaRx stock price today is 1.700.
What Is the Stock Symbol for InflaRx?
The stock symbol for InflaRx is ""IFRX.""
What Stock Exchange Does InflaRx Trade On?
InflaRx is listed and trades on the NASDAQ stock exchange.
Is InflaRx a Good Stock to Buy?
Determining whether InflaRx or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IFRX quote. (ISIN: NL0012661870)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.640
1.760
52 wk Range
0.741
2.949
Earnings results expected in 4 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6401.760
52 wk Range
0.7412.949
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IFRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.525
Upside
+342.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Form 13G InflaRx N.V. For: 12 May- Investing.com
Form 13G InflaRx N.V. For: 14 May- Investing.com
- Form 13G InflaRx N.V. For: 14 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.525
(+342.63% Upside)
Earnings
Latest Release
07/05/2026
EPS / Forecast
-0.08 / -0.14
Revenue / Forecast
-- / 7.75K
Compare IFRX to Peers and Sector
Metrics to compare | IFRX | Sector Sector - Average of metrics from a broad group of related Financial sector companies | Relationship RelationshipIFRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.1x | −5.0x | −0.3x | |
PEG Ratio | −0.29 | −0.01 | 0.00 | |
Price/Book | 5.9x | 3.9x | 2.6x | |
Price / LTM Sales | 7,400.7x | 18.1x | 3.0x | |
Upside (Analyst Target) | 390.0% | 63.2% | 56.3% | |
Fair Value Upside | Unlock | 0.4% | 9.2% | Unlock |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the InflaRx (IFRX) Stock Price Today?
The InflaRx stock price today is 1.700 USD.
What Stock Exchange Does InflaRx Trade On?
InflaRx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for InflaRx?
The stock symbol for InflaRx is "IFRX."
What Is the InflaRx Market Cap?
As of today, InflaRx market cap is 250.400M USD.
What Is InflaRx's Earnings Per Share (TTM)?
The InflaRx EPS (TTM) is -0.617.
When Is the Next InflaRx Earnings Date?
InflaRx will release its next earnings report on 06/08/2026.
From a Technical Analysis Perspective, Is IFRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has InflaRx Stock Split?
InflaRx has split 0 times.
How Many Employees Does InflaRx Have?
InflaRx has 65 employees.
What is the current trading status of InflaRx (IFRX)?
As of 02/08/2026, InflaRx (IFRX) is trading at a price of 1.700 USD, with a previous close of 1.720 USD. The stock has fluctuated within a day range of 1.640 USD to 1.760 USD, while its 52-week range spans from 0.741 USD to 2.949 USD.
What Is InflaRx (IFRX) Price Target According to Analysts?
The average 12-month price target for InflaRx is 7.525 USD, with a high estimate of 13.71066282 USD and a low estimate of 2.94293948 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +342.63% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.